Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Imad, Tarhoni"'
Autor:
Kyle D Anderson, Christian Beckmann, Saskia Heermant, Frank C Ko, Bryan Dulion, Imad Tarhoni, Jeffrey A Borgia, Amarjit S Virdi, Markus A Wimmer, D Rick Sumner, Ryan D Ross
Publikováno v:
JBMR Plus, Vol 7, Iss 11, Pp n/a-n/a (2023)
ABSTRACT An increasing number of patients with type 2 diabetes (T2DM) will require total joint replacement (TJR) in the next decade. T2DM patients are at increased risk for TJR failure, but the mechanisms are not well understood. The current study us
Externí odkaz:
https://doaj.org/article/e5de1822a7364e4cb362b8e66e444812
Autor:
Fei Chu, Nicholas J. Skertich, Jeffrey A. Borgia, Imad Tarhoni, Stephen Szajek, Mary Beth Madonna
Publikováno v:
Surgery Open Science, Vol 6, Iss, Pp 10-14 (2021)
Surgery Open Science
Surgery Open Science
Background: Inhibition of the programmed death ligand 1, programmed death 1 pathway has been successfully used for treatment of multiple advanced adult cancers. However, its use in pediatric osteosarcoma is still in its infancy. In this study, we inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f4b311880ebd1fc0b8ba946d799acef
http://www.sciencedirect.com/science/article/pii/S2589845021000129
http://www.sciencedirect.com/science/article/pii/S2589845021000129
Autor:
Michelle K. Ash, Pavan P. Bhimalli, Byoung-Kyu Cho, Basil Baby Mattamana, Stéphanie Gambut, Imad Tarhoni, Cristina L. Fhied, Anjelica F. Reyes, Samantha J. Welninski, Jaison Arivalagan, Fernanda Negrão, Renu Goel, Todd L. Beck, Thomas J. Hope, Beverly E. Sha, Young Ah Goo, Lena Al-Harthi, João I. Mamede, Jeffrey A. Borgia, Neil L. Kelleher, Jeffrey R. Schneider
Publikováno v:
Cell reports.
Although vaccination efforts have expanded, there are still gaps in our understanding surrounding the immune response to SARS-CoV-2. Measuring IgG Fc glycosylation provides insight into an infected individual's inflammatory state, among other functio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f977381326aa190aa1b15816a348f28
https://pubmed.ncbi.nlm.nih.gov/36493786
https://pubmed.ncbi.nlm.nih.gov/36493786
Autor:
Cristina L, Fhied, Imad, Tarhoni, David, Gerard, Grant M, Lewin, Hita, Moudgalya, Jeffrey R, Schneider, Jeffrey A, Borgia
Publikováno v:
Journal of Visualized Experiments.
Multiplex technologies for interrogating multiple biomarkers in concert have existed for several decades; however, methods to evaluate multiple epitopes on the same analyte remain limited. This report describes the development and optimization of a m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::111d769f112602f7dd9b4e50e6d313ee
https://doi.org/10.3791/63352-v
https://doi.org/10.3791/63352-v
Autor:
Maria Laura Ricardo Silgado, Tangri Apoorva, Imad Tarhoni, Darin Bagar, Muqdad Hasan, Alaa Kubbar, Suruchi Karnik, Sandra Iwuala, Rhonda-Kaye Trusty, Opeyemi Aroyewun, Prama Rashmi, Sandhya Bhusal, Edward Rippe, Syed Salman Hamid Hashmi, Muhammad Tahir, Joseph Mahalli, Allen Gorbonos, Arnav Kamat, Gul Bahtiyar, Giovanna Rodriguez
Publikováno v:
Journal of the Endocrine Society. 6:A377-A377
Introduction Hyperosmolar crisis, which includes diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), is a severe and acute complication of diabetes. The estimated mortality rates of DKA and HHS are 6.8% and 10%, respectively (Beno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ef18cc6cf04e22ce0f725450fb6cb5f
https://doi.org/10.1210/jendso/bvac150.784
https://doi.org/10.1210/jendso/bvac150.784
Autor:
Revathi Kollipara, Jeffrey A. Borgia, Philip Bonomi, Marta Batus, Imad Tarhoni, Mary J. Fidler, Connor Wakefield
Publikováno v:
Journal of immunological methods. 490
Durable tumor regressions are observed in a subset of advanced-stage non-small cell lung cancer (NSCLC) patients receiving PD-1/-L1 targeted immune checkpoint inhibitors (or 'immunotherapy') alone or in combination with chemotherapy. However, the maj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12e1aeba7c5bc0f005f8b630b28114a4
https://pubmed.ncbi.nlm.nih.gov/33434603
https://pubmed.ncbi.nlm.nih.gov/33434603
Autor:
Nicole K. Yun, Jeffrey A. Borgia, Ethan M. Ritz, Mary J. Fidler, Imad Tarhoni, Marta Batus, Christine M. Bestvina, B. Gilmore, P. Bonomi, Sherin J. Rouhani
Publikováno v:
Journal of Thoracic Oncology. 16:S599-S600
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4dbbd6dd1b95d16dd1c3b50f88ed2b78
https://doi.org/10.1016/j.jtho.2021.01.1087
https://doi.org/10.1016/j.jtho.2021.01.1087
Autor:
Marta Batus, Sanjib Basu, Hita Moudgalya, Jeffrey A. Borgia, Wen Rong Lie, Imad Tarhoni, Mary J. Fidler, Philip Bonomi, Danielle Pepin
Publikováno v:
Cancer Research. 81:1621-1621
Introduction: Immune checkpoint inhibitor (ICI) therapy has shown remarkable benefits in treating non-small-cell lung cancer (NSCLC). However, progress beyond PD-L1 expression has not yielded biomarkers that can better select responders to ICI. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f532acd14f304bb2a24f9a92252a003
https://doi.org/10.1158/1538-7445.am2021-1621
https://doi.org/10.1158/1538-7445.am2021-1621
Publikováno v:
Current Molecular Biology Reports. 3:247-253
Lung cancer is the leading cause of cancer-related mortality worldwide. The five-year survival rate is very low in lung cancer patients due to diagnosis at late stages, tumor recurrence, and drug resistance. Recent studies suggest that cancer cells w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d50484f5a53e2096562726593fa78b4c
https://doi.org/10.1007/s40610-017-0080-8
https://doi.org/10.1007/s40610-017-0080-8
Autor:
Jeffrey A. Borgia, Imad Tarhoni, Mary J. Fidler, Sherin J. Rouhani, Brendan A. Gilmore, Philip Bonomi, Ethan M. Ritz, Marta Batus, Nicole K. Yun, Christine M. Bestvina
Publikováno v:
Cancers
Volume 13
Issue 6
Cancers, Vol 13, Iss 1426, p 1426 (2021)
Volume 13
Issue 6
Cancers, Vol 13, Iss 1426, p 1426 (2021)
Background: First-line treatment for patients with non-small cell lung cancer (NSCLC) with a sensitizing epidermal growth factor receptor (EGFR) mutation is a tyrosine kinase inhibitor (TKI). Despite higher response rates and prolonged progression fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b291fb6dda05fac100ca9a97d37641f6
https://doi.org/10.3390/cancers13061426
https://doi.org/10.3390/cancers13061426